Microbix Biosystems Inc. (MBXBF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Microbix Biosystems Inc. (MBXBF) trades at $0.217 with AI Score 46/100 (Grade C). Microbix Biosystems Inc. develops and commercializes biological solutions for human health, focusing on critical materials for the diagnostics industry. Market cap: $29.8M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for MBXBF: MBXBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MBXBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MBXBF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Microbix Biosystems Inc. (MBXBF) Healthcare & Pipeline Overview
Microbix Biosystems Inc. specializes in biological materials for the diagnostics industry, offering antigens, quality assessment products (QAPs), and viral transport medium (DxTM). With a global presence, the company supports clinical lab proficiency testing and assay development, while also developing Kinlytic Urokinase, a biologic thrombolytic drug.
What Is the Investment Thesis for MBXBF?
Microbix Biosystems Inc. presents a focused investment opportunity within the biotechnology sector, driven by its specialized product offerings for the diagnostics industry. The company's QAPs and antigens generate consistent revenue, supporting clinical labs and diagnostic companies globally. A key growth catalyst is the expansion of its DxTM product line, addressing the increasing demand for reliable viral transport solutions. The potential commercialization of Kinlytic Urokinase represents a significant value driver, contingent on successful clinical trials and regulatory approvals. However, the company's negative profit margin of -25.5% and reliance on distribution partnerships pose ongoing risks. Investors should monitor the company's ability to improve profitability and expand its direct sales capabilities.
Based on FMP financials and quantitative analysis
MBXBF Key Highlights
Market capitalization of $29.8M indicates a small-cap company with potential for growth.
- Negative P/E ratio of -7.82 reflects current losses, requiring careful monitoring of profitability trends.
- Gross margin of 46.7% demonstrates the company's ability to maintain profitability at the product level.
- Beta of 0.49 suggests lower volatility compared to the overall market.
- No dividend yield indicates that the company is reinvesting earnings for growth.
Who Are MBXBF's Competitors?
MBXBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BBIXF Bonus BioGroup Ltd. | $0.08 | +0.00% | $93.4M | 48 |
| CLYYF Celyad Oncology S.A. | $0.28 | +0.00% | $12.5M | 61 |
| DTCFF Defence Therapeutics Inc. | $0.34 | -5.17% | $26.1M | 42 |
| ELVAF EvoNext Holdings S.A. | $2.15 | +0.00% | $15.5M | 42 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MBXBF's Key Strengths?
Specialized expertise in developing biological materials for diagnostics.
- Established relationships with key players in the diagnostics industry.
- Proprietary products like DxTM and Kinlytic Urokinase.
- Recurring revenue from quality assessment products (QAPs).
What Are MBXBF's Weaknesses?
Negative profit margin (-25.5%) indicates financial challenges.
- Reliance on distribution partnerships for sales.
- Limited product diversification.
- Small market capitalization ($0.03 billion) may limit access to capital.
What Could Drive MBXBF Stock Higher?
Clinical trial results for Kinlytic Urokinase could drive significant investor interest.
- Expansion of DxTM product line and securing new distribution agreements.
- Increasing demand for diagnostic testing due to global health concerns.
- Potential strategic acquisitions to expand product portfolio.
- Development of new quality assessment products (QAPs) to address emerging needs in clinical laboratories.
What Are the Key Risks for MBXBF?
Financial-distress signal — its Altman Z-Score of 1.72 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-21.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger diagnostics companies with greater resources.
- Regulatory hurdles and delays in obtaining approval for Kinlytic Urokinase.
- Patent expiration risks for key products.
- Negative profit margin and financial challenges.
- Limited liquidity and price volatility due to OTC listing.
What Are the Growth Opportunities for MBXBF?
- Expansion of DxTM Product Line: The market for viral transport media is growing due to increased testing for infectious diseases. Microbix can capitalize on this trend by expanding its DxTM product line and securing additional distribution agreements. This growth opportunity addresses a market estimated to reach $1.5 billion by 2028, offering a significant revenue boost for Microbix.
- Commercialization of Kinlytic Urokinase: Successful clinical trials and regulatory approval for Kinlytic Urokinase would open up a new revenue stream for Microbix in the thrombolytic drug market. This market is projected to reach $4.2 billion by 2027. Securing partnerships with pharmaceutical companies for distribution could accelerate market penetration.
- Geographic Expansion: Microbix can expand its presence in international markets, particularly in Asia and Latin America, where demand for diagnostic products is increasing. Establishing local distribution networks and tailoring product offerings to meet regional needs would be crucial for success.
- Strategic Acquisitions: Microbix can pursue strategic acquisitions of complementary businesses or technologies to expand its product portfolio and market reach. Acquiring companies with established distribution networks or specialized diagnostic capabilities would accelerate growth and enhance competitive positioning. This strategy aligns with the broader trend of consolidation within the biotechnology industry.
- Development of New QAPs: Microbix can invest in the development of new quality assessment products (QAPs) to address emerging needs in clinical laboratories. This includes developing QAPs for new diagnostic tests and expanding the range of parameters covered by existing QAPs. This ongoing innovation is essential for maintaining a competitive edge and capturing a larger share of the QAPs market, estimated at $500 million annually.
What Are MBXBF's Competitive Advantages?
- Specialized Expertise: Deep knowledge and experience in developing and manufacturing biological materials for diagnostics.
- Established Relationships: Strong relationships with lab accreditation organizations, diagnostics companies, and clinical labs.
- Proprietary Products: Ownership of proprietary products like DxTM and Kinlytic Urokinase.
- Quality Assessment Products (QAPs): Niche market with recurring revenue due to regulatory requirements for lab proficiency testing.
What Does MBXBF Do?
Founded in 1988 and headquartered in Mississauga, Canada, Microbix Biosystems Inc. operates as a life science company focused on developing and commercializing biological and technological solutions aimed at improving human health. The company's core business revolves around manufacturing critical biological materials for the diagnostics industry. These materials include a range of antigens used in immunoassays, as well as its laboratory quality assessment products (QAPs). These QAPs play a vital role in supporting clinical lab proficiency testing, assay development and validation, and overall clinical lab workflows. Beyond its established product lines, Microbix leverages its biological expertise and infrastructure to develop proprietary products. A key example is its viral transport medium (DxTM), designed to stabilize patient samples for lab-based testing. The company is also advancing Kinlytic Urokinase, a biologic thrombolytic drug used in the treatment of blood clots. Microbix distributes its QAPs through a network of regional distributors, reaching lab accreditation organizations, diagnostics companies, and clinical labs across North America, Europe, and other international markets. The company's strategic focus on diagnostics and therapeutic solutions positions it within the broader healthcare landscape.
What Products and Services Does MBXBF Offer?
- Develops and manufactures antigens for immunoassays used in diagnostic testing.
- Produces laboratory quality assessment products (QAPs) for clinical lab proficiency testing.
- Offers viral transport medium (DxTM) to stabilize patient samples for lab-based testing.
- Develops Kinlytic Urokinase, a biologic thrombolytic drug for treating blood clots.
- Sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs.
- Distributes products through a network of regional distributors in North America, Europe, and internationally.
How Does MBXBF Make Money?
- Manufacturing and selling antigens for use in diagnostic assays.
- Providing quality assessment products (QAPs) to clinical laboratories for proficiency testing.
- Generating revenue through the sale of viral transport medium (DxTM) for sample stabilization.
- Developing and commercializing Kinlytic Urokinase as a biologic thrombolytic drug.
What Industry Does MBXBF Operate In?
Microbix Biosystems Inc. operates within the biotechnology industry, which is characterized by rapid innovation and evolving regulatory landscapes. The diagnostics market, a key focus for Microbix, is experiencing growth driven by increasing demand for accurate and efficient testing solutions. The competitive landscape includes companies like AHFGIF, BBIXF, CLYYF, DTCFF, and ELVAF, each with varying strengths in specific diagnostic segments. Microbix differentiates itself through its focus on quality assessment products and its development of novel therapeutic solutions like Kinlytic Urokinase.
Who Are MBXBF's Key Customers?
- Lab accreditation organizations
- Diagnostics companies
- Clinical labs
- Pharmaceutical companies (potential customers for Kinlytic Urokinase)
Key Financial Metrics
Return on equity for Microbix Biosystems Inc. stands at -21.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -13.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.35 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.8%, the inverse of the P/E and a quick read on earnings relative to price.
Microbix Biosystems Inc. (MBXBF) Valuation Context
Valued at $29.8M, MBXBF is classified as a micro-cap stock. Relative to its peer group, MBXBF's quantitative score of 46/100 is roughly in line with the peer average of 55/100.
Company Profile
Microbix Biosystems Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Mississauga, CA. The company is led by CEO Cameron L. Groome. MBXBF has traded publicly since 2021.
Financial Health
Microbix Biosystems Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.72 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Microbix Biosystems Inc. revenue of about $18.5M for fiscal 2026, with EPS near $-0.01.
MBXBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized expertise in developing biological materials for diagnostics.
- Established relationships with key players in the diagnostics industry.
- Proprietary products like DxTM and Kinlytic Urokinase.
- Recurring revenue from quality assessment products (QAPs).
Bear Case
- Negative profit margin (-25.5%) indicates financial challenges.
- Reliance on distribution partnerships for sales.
- Limited product diversification.
- Small market capitalization ($0.03 billion) may limit access to capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
MBXBF Latest News
No recent news available for MBXBF.
MBXBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MBXBF.
Price Targets
Wall Street price target analysis for MBXBF.
MBXBF MoonshotScore
What does this score mean?
The MoonshotScore rates MBXBF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Cameron L. Groome
CEO
Cameron L. Groome serves as the CEO of Microbix Biosystems Inc., bringing extensive experience in the biotechnology and healthcare sectors. His background includes leadership roles in various life science companies, focusing on strategic planning, product development, and commercialization. Groome's expertise spans areas such as diagnostics, therapeutics, and medical devices. He holds advanced degrees in business and science, providing a strong foundation for guiding Microbix's growth and innovation strategies.
Track Record: Under Cameron Groome's leadership, Microbix Biosystems Inc. has focused on expanding its product portfolio and strengthening its market position in the diagnostics industry. Key achievements include the development and commercialization of new viral transport medium (DxTM) products and advancements in the clinical development of Kinlytic Urokinase. Groome has also overseen strategic partnerships and distribution agreements to expand the company's reach in North America, Europe, and other international markets.
MBXBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Microbix Biosystems Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited liquidity can make it difficult to buy or sell shares quickly.
- Lack of regulatory oversight increases the risk of fraud or mismanagement.
- Limited information availability makes it challenging to assess the company's financial health.
- Price volatility can lead to significant losses.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's OTC Markets profile for any disclosures or warnings.
- Consult with a financial advisor to understand the risks involved.
- Monitor trading volume and price volatility.
- Understand the company's plans for uplisting to a higher exchange.
- The company has been in operation since 1988.
- Microbix has a portfolio of products and services in the diagnostics industry.
- The company has established relationships with lab accreditation organizations and diagnostics companies.
- CEO Cameron L. Groome has experience in the biotechnology sector.
- The company has a team of 100 employees.
What Investors Ask About Microbix Biosystems Inc. (MBXBF) — Healthcare
What does the AI Score mean for MBXBF?
MBXBF holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Microbix Biosystems Inc. develops and commercializes biological solutions for human health, focusing on critical materials for the diagnostics industry. The company's portfolio includes antigens …
What does Microbix Biosystems Inc. do?
Microbix Biosystems Inc. is a biotechnology company that develops and commercializes biological solutions for the diagnostics industry. Its primary focus is on manufacturing critical biological materials, including antigens for immunoassays and laboratory quality assessment products (QAPs). These products support clinical lab proficiency testing, assay development, and clinical lab workflows.
What do analysts say about MBXBF stock?
Analyst coverage for MBXBF is limited due to its OTC listing and small market capitalization. However, analysts generally focus on the company's growth potential in the diagnostics market, particularly its DxTM product line and the potential commercialization of Kinlytic Urokinase. Key valuation metrics include revenue growth, gross margin, and potential earnings from new products.
What are the main risks for MBXBF?
The main risks for Microbix Biosystems Inc. include its negative profit margin, which indicates financial challenges and the need to improve profitability. Competition from larger diagnostics companies with greater resources poses a threat to its market share. Regulatory hurdles and delays in obtaining approval for Kinlytic Urokinase could impact its commercialization timeline.
How does Microbix Biosystems Inc. manage patent expiration risks?
Microbix Biosystems Inc. manages patent expiration risks through a combination of strategies, including continuous innovation and development of new products and technologies. The company also seeks to extend the lifecycle of existing products through formulation improvements and new applications. Additionally, Microbix actively monitors the competitive landscape and potential biosimilar competition to proactively mitigate any potential impact on its revenue streams.
What revenue streams does Microbix Biosystems Inc. have in healthcare?
Microbix Biosystems Inc. generates revenue from several key streams within the healthcare sector. A significant portion comes from the sale of antigens used in immunoassays, which are critical components in diagnostic testing. The company also derives revenue from its laboratory quality assessment products (QAPs), which are essential for clinical labs to maintain proficiency and accuracy.
What are the key factors to evaluate for MBXBF?
Microbix Biosystems Inc. (MBXBF) holds an AI score of 46/100 (low). presents a focused investment opportunity within the biotechnology sector, driven by its specialized product offerings for the diagnostics industry. Not financial advice.
How frequently does MBXBF data refresh on this page?
MBXBF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MBXBF's recent stock price performance?
Microbix Biosystems Inc. (MBXBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in developing biological materials for diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than major exchange data.
- Analyst coverage for MBXBF is limited.